Navigation Links
Studies Highlight a Revolutionary New Method of Treating Post-Operative Bruising
Date:6/9/2009

Candela's Vbeam Laser Gives Millions of Post-Surgical Patients a New Sense of Freedom

Wayland, MA (PRWEB) June 9, 2009 -- Candela Corporation (NASDAQ: CLZR) announced today that two studies have reported superior results on patients who benefited from the Candela Vbeam® laser treatments for bruising resulting from cosmetic procedures. The studies concluded that the Vbeam pulsed-dye laser significantly expedited the healing process, improved outcomes, and provided greater overall patient satisfaction.

A study published in the March/April 2009 edition of the Archives of Facial Plastic Surgery, entitled: "Pulsed-Dye Laser for Treating Ecchymoses After Facial Cosmetic Procedures" by DeFatta, R. J., Krishna, S., and Williams, E. F., III concluded that "the Vbeam laser treatment resulted in a 63% mean improvement in ecchymoses scores within forty-eight (48) to seventy-two (72) hours."

The second study, a 2009 ASLMS abstract, entitled: "A Simple Solution to a Common Problem" evaluated the effectiveness and safety of the long-pulse PDL (the Vbeam) for the treatment of ecchymoses. In this study by Elizabeth Hale, M.D., Julie Karen, M.D., Chris Hunzeker, M.D., Elliot Weiss, M.D., Leonard Bernstein, M.D., Lori Brightman, M.D., Anne Chapas, M.D., and Roy Geronemus, M.D. results showed that twenty-four hours post-treatment with the Vbeam laser, the average improvement was 62% and 13% for treated and untreated bruises, respectively.

Edwin F. Williams, M.D., Director, The Williams Center Plastic Surgery Specialists, and nationally recognized plastic surgeon pioneered this breakthrough Vbeam treatment. "Anytime you penetrate the skin there is a potential for bruising and we find that it is the bruising which occurs after many of these procedures that prevents patients from getting out into the public. It is extremely difficult to cover these
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Page: 1 2 3 4

Related medicine news :

1. ACTEMRA(R) (tocilizumab) Studies to be Featured at the European League Against Rheumatism (EULAR) Congress
2. AstraZeneca Studies Show Relief of Nighttime Heartburn and Reduction in GERD-Related Sleep Disturbances
3. Transcept Pharmaceuticals Presents Data from Studies of Two Product Candidates at Annual Meeting of the American Psychiatric Association
4. Genomic Health to Present Multiple New Studies at the American Society of Clinical Oncology Annual Meeting
5. Studies Reveal Exposure to Pesticides During Pregnancy Increases Risk of Premature Birth, Low-Birth Weight, Neurological Problems and Diabetes
6. Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Sarcoma and Osteosarcoma: Phase I/II and Phase II Studies, ASCO 2009
7. 2 studies examine medical consequences of police use of force during restraint
8. Two Studies at AACE 2009 Annual Meeting Highlight Effects of Welchol(R) (colesevelam HCl) on Blood Glucose and LDL-C in Patients with Type 2 Diabetes
9. Studies show LAM patients participate in clinical trials to help others, not themselves
10. Traumatic brain injury haunts children for years with variety of functional problems: Two studies
11. Review finds conflicts of interest in many cancer studies
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Studies Highlight a Revolutionary New Method of Treating Post-Operative Bruising 
Studies Highlight a Revolutionary New Method of Treating Post-Operative Bruising
Other Medicine News:Health News:Prime Healthcare Services to Acquire Three Hospitals from Tenet Healthcare Corporation 2Health News:Meetings with Pre-Screened Verified China Suppliers Help 14 Top Buyers, Including Brookstone and Staples, Save Time and Cut Sourcing Costs 2Health News:Meetings with Pre-Screened Verified China Suppliers Help 14 Top Buyers, Including Brookstone and Staples, Save Time and Cut Sourcing Costs 3Health News:Meetings with Pre-Screened Verified China Suppliers Help 14 Top Buyers, Including Brookstone and Staples, Save Time and Cut Sourcing Costs 4Health News:More girls than boys benefit from breastfeeding, Hopkins Children's research shows 2Health News:More girls than boys benefit from breastfeeding, Hopkins Children's research shows 3Health News:Bunk beds pose dangers to kids and adults 2Health News:Bunk beds pose dangers to kids and adults 3Health News:Large study identifies most costly adverse events in children's hospitals 2Health News:First study to examine vitamin D insufficiency in pediatric patients with low bone density 2
Breaking Medicine Technology:Giant Eagle(R) Pharmacy Receives Award for Operational Excellence 2Reportlinker Adds US Home Healthcare Equipment & Services Market: An Analysis 2Reportlinker Adds US Home Healthcare Equipment & Services Market: An Analysis 3Reportlinker Adds US Home Healthcare Equipment & Services Market: An Analysis 4Reportlinker Adds US Home Healthcare Equipment & Services Market: An Analysis 5Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 2Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 3Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 4Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 5Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 6Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 7Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 8Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 9Back to School Dramatic Medical Help and Hope for the Learning Disabled 57297 1Back to School Dramatic Medical Help and Hope for the Learning Disabled 57297 2Back to School Dramatic Medical Help and Hope for the Learning Disabled 57297 318 month Follow up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory Aggressive Non Hodgkins Lymphoma Continues to Demonstra 5009 118 month Follow up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory Aggressive Non Hodgkins Lymphoma Continues to Demonstra 5009 218 month Follow up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory Aggressive Non Hodgkins Lymphoma Continues to Demonstra 5009 318 month Follow up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory Aggressive Non Hodgkins Lymphoma Continues to Demonstra 5009 418 month Follow up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory Aggressive Non Hodgkins Lymphoma Continues to Demonstra 5009 5UNC study 3A Color coded chart improves parents understanding of body mass index 9942 1UNC study 3A Color coded chart improves parents understanding of body mass index 9942 2